|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: Results of a systematic review显示文摘AIM:To investigate adherence rates in tumor necrosis factor-α (TNF-α)-inhibitors in Crohn's disease (CD) and rheumatoid arthritis (RA) by systematic review of medical literature. METHODS:A structured search of PubMed between 2001 and 2011 was conducted to identify publications that assessed treatment with TNF-α inhibitors providing data about adherence in CD and RA. Therapeutic agents of interest where adalimumab, infliximab and etanercept, since these are most commonly used for both diseases. Studies assessing only drug survival or continuation rates were excluded. Data describing adherence with TNF-α inhibitors were extracted for each selected study. Given the large variation between definitions of measurement of adherence, the definitions as used by the authors where used in our calculations. Data were tabulated and also presented descriptively. Sample size-weighted pooled proportions of patients adherent to therapy and their 95%CI were calculated.To compare adherence between infliximab, adalimumab and etanercept, the adherence rates where graphed alongside two axes. Possible determinants of adherence were extracted from the selected studies and tabulated using the presented OR. RESULTS:Three studies on CD and three on RA were identified, involving a total of 8147 patients (953 CD and 7194 RA). We identified considerable variation in the definitions and methodologies of measuring adherence between studies. The calculated overall sample size-weighted pooled proportion for adherence to TNF-α inhibitors in CD was 70% (95%CI:67%-73%) and 59% in RA (95%CI:58%-60%). In CD the adherence rate for infliximab (72%) was highercompared to adalimumab (55%), with a relative risk of 1.61 (95%CI:1.27-2.03), whereas in RA adherence for adalimumab (67%) was higher compared to both infliximab (48%) and etanercept (59%), with a relative risk of 1.41 (95%CI:1.3-1.52) and 1.13 (95%CI:1.10-1.18) respectively. In comparative studies in RA adherence to infliximab was better than etanercept and etanercept did better than adalimumab. In three studies, the most consistent factor associated with lower adherence was female gender. Results for age, immunomodulator use and prior TNF-α inhibitors use were conflicting. CONCLUSION:One-third of both CD and RA patients treated with TNF-α inhibitors are non-adherent. Female gender was consistently identified as a negative determinant of adherence. | Herma H Fidder Maartje MJ Singendonk Mike van der Have Bas Oldenburg Martijn GH van Oijen | 2013 | World Journal of Gastroenterology2013，19，27： | 2 |
| 2 | Inhibition of vascular endothelial growth factor(VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165 显示文摘 | Soker S Gollamudi-Payne S Fidder H | 1997 | J Biol Chem1997，272，31： | 1 |
| 3 | Clinical and demographic characterization of Jewish Crohn's disease patients in Israel显示文摘 | AVIDAN B LAHAV M | 2003 | J Clin Gastroenterol2003，36，1： | 1 |
| 4 | Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain显示文摘 | Soker S Fidder H Neufeld G | 1996 | J Biol Chem1996，271，10： | 1 |
| 5 | Inhibition of vascular endothelial growth factor(VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165 显示文摘 | Soker S Gollamudi-Payne S Fidder H | 1997 | J Biol Chem1997，272，31： | 1 |
| 6 | Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165 显示文摘 | Soker S Gollamudi-Payne S Fidder H | 1997 | J Biol Chem1997，272，31： | 1 |
| 7 | 查看详情显示文摘 | Greve C Preketes N. K Fidder H Costard R. Koeppe B. Heisler I.A. Mukamel S. Temps F. Nibbering E.T.J. Elsaes-ser T | | 0，，： | 1 |
| 8 | Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort显示文摘 | Schnitzler F Fidder H Ferrante M | 2009 | Gut2009，58，4： | 1 |
| 9 | Long-term Outcome of Treatment with Infliximab in 614 Patients with Crohn's Disease:Results from a Single-centre Cohort显示文摘 | Schnitzler F Fidder H Ferrante M at a1 | 2009 | Gut2009，58，4： | 1 |
| 10 | Agonists of MAS oncogene and angiotensin Ⅱ type 2 receptors attenuate cardiopulmonary disease in rats with neonatal hyperoxia-in- duced lung injury显示文摘 | Wagenaar G T Laghmani el H Fidder M | 2013 | Am J Physiol Lung Cell Mol Physiol2013，305，5： | 1 |
| 11 | Somatostatin inhibits pro - inflammatory cytokine secretion from rat hepatic stellate cells 显示文摘 | LANG A SAKHNINI E FIDDER H H | 2005 | Liver Int2005，25，4： | 1 |
| 12 | Inhibition of vascular endothelial growth factor(VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165显示文摘 | Soker S Gollamudi-Payne S Fidder H | 1997 | J Biol Chem1997，272，31： | 1 |
| 13 | Optical Properties of Disordered Molecular Aggregates:A Numerical Study显示文摘 | FIDDER H KNOESTER J WIERSMA D A | 1991 | J Chem Phys1991，95，11： | 1 |
| 14 | Nonlinear Complex Susceptibility of Cresyl Violet Solution Measured with a Dynamic Grating Method显示文摘 | FIDDER H KNOESTER J WIERSMA D A | 1989 | IEEE J Quantum Electron1989，25，3： | 1 |
| 15 | Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease:results from a single-centre cohort显示文摘 | Schnitzler F Fidder H Ferrante M | 2009 | Gut2009，58，4： | 1 |
| 16 | Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain显示文摘 | Soker S Fidder H Neufeld G | 1996 | J Biol Chem1996，271，10： | 1 |
| 17 | Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease:results from a single-centre cohort显示文摘 | Schnitzler F Fidder H Ferrante M | 2009 | Gut2009，58，4： | 1 |
| 18 | Mucosal heal- ing predicts long-term outcome of maintenance therapy with infliximab in Crohn' s disease 显示文摘 | Schnitzler F Fidder H Ferrante M | 2009 | Inflamm Bowel Dis2009，15，9： | 1 |
| 19 | Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165显示文摘 | Soker S Gollamudi-payne S Fidder H | 1997 | J Biol Chem1997，272，31： | 1 |
| 20 | Characterization of novel vascular endothelial growth factor(VEGF) receptors on tumor ceils that bind VEGFI65 via its exon 7-encoded domain显示文摘 | Soker S Fidder H Neufeld G | 1996 | J Biol Chem1996，271，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员